Eupraxia Pharmaceuticals Inc. (TSX:EPRX)
Canada
· Delayed Price · Currency is CAD 9.77
-0.10 (-1.01%)
Apr 28, 2026, 4:00 PM EST
Eupraxia Pharmaceuticals Employees
Eupraxia Pharmaceuticals had 49 employees as of December 31, 2025. The number of employees increased by 16 or 48.48% compared to the previous year.
Employees
49
Change (1Y)
16
Growth (1Y)
48.48%
Revenue / Employee
n/a
Profits / Employee
-1.15M CAD
Market Cap
607.04M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Bright Minds Biosciences | 26 |
| Satellos Bioscience | 21 |
| Helix BioPharma | 7 |
| Sernova Biotherapeutics | 8 |
| Medicenna Therapeutics | 18 |
| BriaCell Therapeutics | 16 |
Eupraxia Pharmaceuticals News
- 6 days ago - Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting - GlobeNewsWire
- 5 weeks ago - Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst - Benzinga
- 6 weeks ago - Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option - GlobeNewsWire
- 2 months ago - Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants - GlobeNewsWire
- 2 months ago - Eupraxia Pharmaceuticals Announces Proposed Public Offering - GlobeNewsWire
- 3 months ago - Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy - GlobeNewsWire
- 5 months ago - Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI - GlobeNewsWire